ABVC Biopharma Files 8-K: Agreements & Equity Sales

TL;DR

ABVC Bio just dropped an 8-K: new deals and stock sales filed. Keep an eye on this.

AI Summary

On November 4, 2024, ABVC Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company is incorporated in Nevada and its fiscal year ends on December 31.

Why It Matters

This 8-K filing indicates significant corporate actions, including definitive agreements and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — Filings related to definitive agreements and unregistered equity sales can introduce uncertainty and potential dilution, warranting a medium risk assessment.

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Registrant
• November 4, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-40700 (filing_id) — Commission File Number
• 26-0014658 (tax_id) — IRS Employer Identification No.
• 44370 OLD WARM SPRINGS BLVD. (address) — Business Address
• FREMONT (city) — Business Address City
• CA (state) — Business Address State
• 94538 (zip_code) — Business Address Zip

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
• $0.75 — on Stock at a reduced exercise price of $0.75 per share. Lind also received a new war
• $1.00 — the five-year anniversary thereof, for $1.00 per share (the " May Warrant "). On No
• $0.42 — r share, at a reduced exercise price of $0.42 per share. Other than the Outstanding E

Filing Documents

• ea021970901-8k_abvcbio.htm (8-K) — 30KB
• ea021970901ex10-1_abvcbio.htm (EX-10.1) — 33KB
• 0001213900-24-094178.txt ( ) — 243KB
• abvc-20241104.xsd (EX-101.SCH) — 3KB
• abvc-20241104_lab.xml (EX-101.LAB) — 33KB
• abvc-20241104_pre.xml (EX-101.PRE) — 22KB
• ea021970901-8k_abvcbio_htm.xml (XML) — 3KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. As previously reported, over the past year, ABVC BioPharma, Inc. (the " Company ") has entered into three securities purchase agreements with Lind Global Fund II, LP (" Lind "), pursuant to which the Company has issued to Lind: (i) 3,527,778 shares of the Company's common stock, par value $0.001 per share (the " Common Stock ") underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of February 23, 2023 between the Company and Lind (the "Lind Transaction"); (ii) 5,291,667 shares of Common Stock underlying a common stock purchase warrant pursuant to the Lind Transaction; (iii) 342,857 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of November 17, 2023 between the Company and Lind (the "2 nd Lind Transaction"); (iv) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 2 nd Lind Transaction; (v) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the "3 rd Lind Transaction," together with the Lind Transaction and 2 nd Lind Transaction, the "Initial Lind Transactions") and (vi) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3 rd Lind Transaction (all of the warrants issued to Lind are hereinafter referred to as the " Existing Warrants "). On May 22, 2024, the Company and Lind entered into a letter agreement (the " May Letter Agreement "), pursuant to which Lind exercised, for cash, 1,000,000 of the Existing Warrants (the number of warrants so exercised is herein referred to as the " Outstanding Exercised Warrants ") to purchase shares of Common Stock at a reduced exercise price of $0.75 per share. Lind also received a new warrant to purchase 1,000,00

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit 10.1 Letter Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. November 4, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR